Literature DB >> 17325038

Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions.

Chun-Song Yang1, Hong-Wu Xin, Joshua B Kelley, Adam Spencer, David L Brautigan, Bryce M Paschal.   

Abstract

We describe a mechanism for protein phosphatase 2A (PP2A) targeting to the androgen receptor (AR) and provide insight into the more general issue of kinase and phosphatase interactions with AR. Simian virus 40 (SV40) small t antigen (ST) binding to N-terminal HEAT repeats in the PP2A A subunit induces structural changes transduced to C-terminal HEAT repeats. This enables the C-terminal HEAT repeats in the PP2A A subunit, including HEAT repeat 13, to discriminate between androgen- and androgen antagonist-induced AR conformations. The PP2A-AR interaction was used to show that an AR mutant in prostate cancer cells (T877A) is activated by multiple ligands without acquiring the same conformation as that induced by androgen. The correlation between androgen binding to AR and increased phosphorylation of the activation function 1 (AF-1) region implies that changes in AR conformation or chaperone composition are causal to kinase access to phosphorylation sites. However, AF-1 phosphorylation sites are kinase accessible prior to androgen binding. This suggests that androgens can enhance the phosphorylation state of AR either by negatively regulating the ability of the ligand-binding domain to bind phosphatases or by inducing an AR conformation that is resistant to phosphatase action. SV40 ST subverts this mechanism by promoting the direct transfer of PP2A onto androgen-bound AR, resulting in multisite dephosphorylation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325038      PMCID: PMC1899975          DOI: 10.1128/MCB.02411-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  49 in total

1.  A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1)

Authors:  L V Nazareth; D L Stenoien; W E Bingman; A J James; C Wu; Y Zhang; D P Edwards; M Mancini; M Marcelli; D J Lamb; N L Weigel
Journal:  Mol Endocrinol       Date:  1999-12

2.  Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase.

Authors:  P B Joel; A M Traish; D A Lannigan
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

3.  A novel simian virus 40 early-region domain mediates transactivation of the cyclin A promoter by small-t antigen and is required for transformation in small-t antigen-dependent assays.

Authors:  A Porrás; J Bennett; A Howe; K Tokos; N Bouck; B Henglein; S Sathyamangalam; B Thimmapaya; K Rundell
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

4.  An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter.

Authors:  K B Cleutjens; H A van der Korput; C C van Eekelen; H C van Rooij; P W Faber; J Trapman
Journal:  Mol Endocrinol       Date:  1997-02

5.  Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo.

Authors:  Y Zhang; C A Beck; A Poletti; J P Clement; P Prendergast; T T Yip; T W Hutchens; D P Edwards; N L Weigel
Journal:  Mol Endocrinol       Date:  1997-06

6.  B cell receptor-associated protein alpha4 displays rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A.

Authors:  K Murata; J Wu; D L Brautigan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

7.  Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity.

Authors:  E Langley; J A Kemppainen; E M Wilson
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

8.  Androgen-independent prostate cancer progression in the TRAMP model.

Authors:  J R Gingrich; R J Barrios; M W Kattan; H S Nahm; M J Finegold; N M Greenberg
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

9.  Activation of the human androgen receptor through a protein kinase A signaling pathway.

Authors:  L V Nazareth; N L Weigel
Journal:  J Biol Chem       Date:  1996-08-16       Impact factor: 5.157

10.  Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.

Authors:  S Kasper; P C Sheppard; Y Yan; N Pettigrew; A D Borowsky; G S Prins; J G Dodd; M L Duckworth; R J Matusik
Journal:  Lab Invest       Date:  1998-06       Impact factor: 5.662

View more
  19 in total

1.  Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro.

Authors:  Leonard C Shank; Joshua B Kelley; Daniel Gioeli; Chun-Song Yang; Adam Spencer; Lizabeth A Allison; Bryce M Paschal
Journal:  J Biol Chem       Date:  2008-02-12       Impact factor: 5.157

Review 2.  PP2A as a master regulator of the cell cycle.

Authors:  Nathan Wlodarchak; Yongna Xing
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-02-24       Impact factor: 8.250

3.  Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.

Authors:  Kimberly McClinch; Rita A Avelar; David Callejas; Sudeh Izadmehr; Danica Wiredja; Abbey Perl; Jaya Sangodkar; David B Kastrinsky; Daniela Schlatzer; Maxwell Cooper; Janna Kiselar; Agnes Stachnik; Shen Yao; Divya Hoon; Daniel McQuaid; Nilesh Zaware; Yixuan Gong; David L Brautigan; Stephen R Plymate; Cynthia C T Sprenger; William K Oh; Alice C Levine; Alexander Kirschenbaum; John P Sfakianos; Rosalie Sears; Analisa DiFeo; Yiannis Ioannou; Michael Ohlmeyer; Goutham Narla; Matthew D Galsky
Journal:  Cancer Res       Date:  2018-01-22       Impact factor: 12.701

4.  Identification of androgen receptor phosphorylation in the primate ovary in vivo.

Authors:  Iain J McEwan; Dagmara McGuinness; Colin W Hay; Robert P Millar; Philippa T K Saunders; Hamish M Fraser
Journal:  Reproduction       Date:  2010-04-20       Impact factor: 3.906

5.  Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1.

Authors:  Shaoyong Chen; Cristina T Kesler; Bryce M Paschal; Steven P Balk
Journal:  J Biol Chem       Date:  2009-07-21       Impact factor: 5.157

Review 6.  Androgen receptor phosphorylation: biological context and functional consequences.

Authors:  Yulia Koryakina; Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-01-14       Impact factor: 5.678

Review 7.  Nuclear actin and actin-binding proteins in the regulation of transcription and gene expression.

Authors:  Bin Zheng; Mei Han; Michel Bernier; Jin-kun Wen
Journal:  FEBS J       Date:  2009-05       Impact factor: 5.542

8.  Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas.

Authors:  George P Skliris; Brian G Rowan; Mariam Al-Dhaheri; Christopher Williams; Sandy Troup; Sanela Begic; Michelle Parisien; Peter H Watson; Leigh C Murphy
Journal:  Breast Cancer Res Treat       Date:  2008-12-23       Impact factor: 4.872

9.  Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor.

Authors:  Li Ni; Ryan Llewellyn; Cristina T Kesler; Joshua B Kelley; Adam Spencer; Chelsi J Snow; Leonard Shank; Bryce M Paschal
Journal:  Mol Cell Biol       Date:  2013-10-07       Impact factor: 4.272

10.  SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.

Authors:  Sanna Kaikkonen; Tiina Jääskeläinen; Ulla Karvonen; Miia M Rytinki; Harri Makkonen; Daniel Gioeli; Bryce M Paschal; Jorma J Palvimo
Journal:  Mol Endocrinol       Date:  2008-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.